TY - JOUR
T1 - Tumor Receptor-Mediated in Vivo Modulation of the Morphology, Phototherapeutic Properties, and Pharmacokinetics of Smart Nanomaterials
AU - Zhang, Lu
AU - Wu, Yi
AU - Yin, Xingbin
AU - Zhu, Zheng
AU - Rojalin, Tatu
AU - Xiao, Wenwu
AU - Zhang, Dalin
AU - Huang, Yanyu
AU - Li, Longmeng
AU - Baehr, Christopher M.
AU - Yu, Xingjian
AU - Ajena, Yousif
AU - Li, Yuanpei
AU - Wang, Lei
AU - Lam, Kit S.
N1 - Funding Information:
This work was supported by NIH/NCI Grants (R01CA232845, R01CA199668, U01CA198880, and R01CA115483), NIH/NICHD Grant (R01HD086195), NIH/NIBIB Grant (R01EB012569), and National Natural Science Foundation of China (51890891).
PY - 2021
Y1 - 2021
N2 - To be clinically efficacious, nanotherapeutic drugs need to reach disease tissues reliably and cause limited side effects to normal organs and tissues. Here, we report a proof-of-concept study on the development of a smart peptidic nanophototherapeutic agent in line with clinical requirements, which can transform its morphology from nanoparticles to nanofibrils at the tumor sites. This in vivo receptor-mediated transformation process resulted in the formation and prolonged tumor-retention of highly ordered (J-aggregate type of photosensitizer) photosensitive peptide nanofibrillar network with greatly enhanced photothermal and photodynamic properties. This strategy of "multiple daily low-intensity laser radiation after each intravenous injection of significantly low-dose of nanomaterials"demonstrated effective elimination of 4T1 orthotopic syngeneic breast cancer in mice. The technology for nanomaterial modulation based on living cell surface receptors, in this case tumor-associated α3β1 integrin, has great potential for clinical translation and is expected to improve the therapeutic efficacy against many cancers.
AB - To be clinically efficacious, nanotherapeutic drugs need to reach disease tissues reliably and cause limited side effects to normal organs and tissues. Here, we report a proof-of-concept study on the development of a smart peptidic nanophototherapeutic agent in line with clinical requirements, which can transform its morphology from nanoparticles to nanofibrils at the tumor sites. This in vivo receptor-mediated transformation process resulted in the formation and prolonged tumor-retention of highly ordered (J-aggregate type of photosensitizer) photosensitive peptide nanofibrillar network with greatly enhanced photothermal and photodynamic properties. This strategy of "multiple daily low-intensity laser radiation after each intravenous injection of significantly low-dose of nanomaterials"demonstrated effective elimination of 4T1 orthotopic syngeneic breast cancer in mice. The technology for nanomaterial modulation based on living cell surface receptors, in this case tumor-associated α3β1 integrin, has great potential for clinical translation and is expected to improve the therapeutic efficacy against many cancers.
KW - clinical translation
KW - in vivo self-assembly
KW - nanofibrillar transformation
KW - phototherapeutic improvement
KW - receptor-mediated
UR - http://www.scopus.com/inward/record.url?scp=85098796465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098796465&partnerID=8YFLogxK
U2 - 10.1021/acsnano.0c05065
DO - 10.1021/acsnano.0c05065
M3 - Article
C2 - 33332957
AN - SCOPUS:85098796465
JO - ACS Nano
JF - ACS Nano
SN - 1936-0851
ER -